CYP4F22 Inhibitors
CYP4F22 inhibitors encompass a diverse range of chemical compounds that indirectly influence the activity of the CYP4F22 enzyme by interacting with various cellular pathways and regulatory mechanisms. These inhibitors are not specifically designed to target CYP4F22 but can lead to its functional inhibition through the modulation of related enzymes and signaling pathways. For example, azole antifungals (such as ketoconazole, itraconazole, miconazole, fluconazole, and clotrimazole) are known for their broad inhibition of cytochrome P450 enzymes, which can have downstream effects on the function of CYP4F22. The mechanism involves competitive binding or alteration of enzyme cofactors, which can lead to reduced CYP4F22 activity as a secondary effect.
Some inhibitors act by modulating gene expression through nuclear receptors, as seen with retinoic acid and isotretinoin, which can suppress the expression of CYP enzymes by activating retinoid receptors and influencing gene regulation. Others, like pioglitazone, exert their effects through the activation of peroxisome proliferator-activated receptors, which can indirectly decrease CYP4F22 expressionwithin the broader context of lipid metabolism and associated gene expression. Montelukast, by altering leukotriene pathways, and simvastatin, through its impact on cholesterol synthesis, both modify the lipid landscape in a way that can affect CYP4F22 activity. Nicotine's induction of certain CYP enzymes, followed by a subsequent down-regulation, demonstrates how compounds can exert complex regulatory effects on the expression and function of CYP4F22.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole, an antifungal agent, is known to inhibit cytochrome P450 enzymes. By inhibiting CYP3A4, it may cause an increase in endogenous retinoic acid, which could down-regulate CYP4F22 expression as part of a negative feedback mechanism. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid regulates gene expression through retinoid receptors. Excess retinoic acid can suppress the expression of CYP enzymes, including CYP4F22, by altering retinoid-mediated signaling. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Itraconazole, a triazole compound, is another inhibitor of cytochrome P450 enzymes. It can indirectly inhibit CYP4F22 by modulating the availability of heme, an essential cofactor for CYP enzyme activity. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $65.00 $157.00 | 2 | |
Miconazole, primarily an antifungal, inhibits CYP enzymes. By reducing the activity of CYP3A4, it can lead to changes in lipid metabolism that indirectly influence CYP4F22 activity. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Fluconazole is a weaker inhibitor of CYP enzymes compared to other azoles but can still contribute to decreased CYP4F22 function by modulating the cytochrome P450 activity, influencing fatty acid metabolism. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $41.00 $56.00 | 6 | |
Clotrimazole, an imidazole antifungal, inhibits CYP enzymes. Its effect on CYP3A4 can lead to altered lipid profiles, potentially decreasing CYP4F22 activity due to substrate competition. | ||||||
13-cis-Retinoic acid | 4759-48-2 | sc-205568 sc-205568A | 100 mg 250 mg | $74.00 $118.00 | 8 | |
Isotretinoin, a synthetic retinoid, affects the expression of CYP enzymes including CYP4F22. By binding to retinoid receptors, it can suppress the expression of CYP4F22 through retinoid-mediated gene regulation. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Pioglitazone is a thiazolidinedione that can alter CYP enzyme activity by activating PPAR-gamma, which influences the expression of various CYP enzymes, potentially downregulating CYP4F22 as part of the regulatory network. | ||||||
Montelukast Sodium | 151767-02-1 | sc-202231 sc-202231A sc-202231B | 10 mg 25 mg 250 mg | $50.00 $83.00 $158.00 | 5 | |
Montelukast, a leukotriene receptor antagonist, can interfere with CYP enzymes involved in leukotriene metabolism. This could lead to a decrease in CYP4F22 activity due to shared pathways in lipid metabolism. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin, a statin class drug, is metabolized by CYP3A4 and can influence other CYP enzymes through competitive inhibition, potentially leading to decreased CYP4F22 activity due to altered cholesterol synthesis pathways. | ||||||